ArticleVeterinary medicine and science2026
Serum and Urine Nerve Growth Factor and Glycosaminoglycan Levels in Obstructive and Non-Obstructive Feline Urolithiasis and Interstitial Cystitis.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFeline interstitial cystitis (FIC) results from complex interactions between the urinary bladder, nervous system, adrenal glands and the cat's living environment. Following FIC, urolithiasis is the second most common cause of feline lower urinary tract disease (FLUTD), often producing clinical signs that mimic those of obstructive FIC.
objectivesThis study aimed to assess the diagnostic utility of serum and urine concentrations of nerve growth factor (NGF) and glycosaminoglycans (GAGs) in cats with urolithiasis or interstitial cystitis, under both obstructive and non-obstructive conditions.
methodsThe study included 90 cats, comprising 80 cats with clinical signs of FLUTD and 10 healthy controls. Group classification was based on clinical, laboratory and ultrasonographic examinations, as well as multimodal environmental modification (MEMO) evaluation criteria. Cats diagnosed with urolithiasis or FIC were further categorised into obstructive (urolithiasis/obstructive [URO/Ob], FIC/Ob) and non-obstructive (urolithiasis/non-obstructive [URO/Non-Ob], FIC/Non-Ob) subgroups.
resultsMild changes were noted in CBC and serum biochemistry. Serum and urine NGF levels were elevated in URO/Ob, FIC/Ob and FIC/Non-Ob groups but not in URO/Non-Ob. Serum and urine GAG levels were reduced in all groups except URO/Ob. In obstructive cases, serum (AUC = 0.693) and urine GAG (AUC = 0.629) showed moderate/acceptable diagnostic performance in distinguishing URO/Ob from FIC/Ob. In non-obstructive cases, serum (AUC = 0.622) and urine NGF (AUC = 0.612) demonstrated limited to moderate ability to differentiate FIC/Non-Ob from URO/Non-Ob.
conclusionsElevated serum and urine NGF concentrations in cats with FIC have been associated with increased severity of bladder inflammation and tissue injury. In contrast, reduced urine GAG concentrations, observed in all groups except the URO/Ob group, may facilitate bladder inflammation by increasing urothelial permeability. Accordingly, serum and urine GAG levels in obstructive cases and serum and urine NGF levels in non-obstructive cases may provide clinically relevant insights into both the pathophysiology and diagnostic evaluation of FLUTD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.